Advertisement
New Zealand markets open in 7 hours 53 minutes
  • NZX 50

    11,627.86
    -54.53 (-0.47%)
     
  • NZD/USD

    0.6138
    +0.0018 (+0.29%)
     
  • ALL ORDS

    7,975.10
    -64.80 (-0.81%)
     
  • OIL

    81.01
    +0.28 (+0.35%)
     
  • GOLD

    2,340.60
    +9.40 (+0.40%)
     

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?